Lys350
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys350  -  SATB2 (human)

Site Information
PPIPRAVkPEPTNSS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2894438

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , modification-specific antibody ( 2 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Disease tissue studied:
multiple myeloma ( 2 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 2 ) , HeLa (cervical) [SUMO2 (human), transfection, SUMO2 K0 Q87R (lysine-deficient SUMO2, with Q87R to create convenient Trypsin cleavage site)] ( 1 ) , J558L (B lymphocyte) ( 2 )

Upstream Regulation
Regulatory protein:
PIAS2 (human) ( 2 ) , PIAS3 (human) ( 2 ) , PIAS4 (human) ( 2 )

Downstream Regulation
Effects of modification on SATB2:
intracellular localization ( 2 ) , molecular association, regulation ( 2 )
Effects of modification on biological processes:
transcription, inhibited ( 2 )
Inhibit interaction with:
DNA ( 2 )

References 

1

Hendriks IA, et al. (2014) Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol 21, 927-36
25218447   Curated Info

2

Dobreva G, Dambacher J, Grosschedl R (2003) SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev 17, 3048-61
14701874   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.